Still unmet needs in the rapidly growing US breast cancer drug market

17 May 2012

Despite there being around 27 drugs on the market indicated for the treatment of breast cancer, there is currently an unmet need to treat patients, according to new research from Frost & Sullivan.

Consequently, there are abounding opportunities for pharmaceutical manufacturers, as breast cancer is the second most common cancer among women. There are currently 55 breast cancer therapeutic drugs in the developmental phase in the USA, with additional drugs expected to enter this stage in the years to come.

Frost & Sullivan's new analysis, titled A Product and Pipeline Analysis of the US Breast Cancer Therapeutics Market, highlights the current market landscape, providing a competitive analysis of all marketed and pipeline drugs in this segment. Based on the research findings, Frost & Sullivan expects 24 drugs will launch for the treatment of breast cancer in the USA between 2012 and 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >